Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an “important catalyst,” the analyst tells investors in a research note. Cantor views the company as a “pure play” on RNA editing.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.

• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on PRQR:

Disclaimer & DisclosureReport an Issue

• ProQR Therapeutics initiated with an Outperform at Evercore ISI

• ProQR Announces New CFO and CMO to Drive Growth

• ProQR Therapeutics appoints Hom as CFO, Lopez as CMO

• ProQR Therapeutics Advances RNA Editing Pipeline

• ProQR’s Axiomer Technology and AX-0810: A Promising Buy Rating with Increased Price Target